Cloudbyz

MARCH 5, 2024

Biologics: Biologics are large, complex molecules, often proteins, that are produced using living cells. Mode of Action : Small Molecules: They often work by binding to specific sites on target proteins to inhibit or activate their function, which can affect various biological pathways inside the cell.

Development 78

Development Drugs Manufacturing Immune Response 78

Drug Discovery World

OCTOBER 18, 2022

Enanta Pharmaceuticals, a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, has dosed the first subject in its Phase I clinical trial of EDP-323, a novel, oral L-protein inhibitor in development for the treatment of respiratory syncytial virus (RSV). .

In-Vitro 52

In-Vitro Genotype Bioavailability Clinical Trials 52

pharmaphorum

NOVEMBER 9, 2022

If these mitochondrial therapeutics were to be successful in clinical trials, they would be the first disease-modifying medicine to actually prevent or delay progression of these diseases. In ALS , the protein TDP-43 triggers neuroinflammation via activation of the innate immune sensor STING.

In-Vitro 52

In-Vitro Bioavailability Medicine Clinical Trials 52

Delveinsight

JANUARY 7, 2021

The immunotherapy pipeline is led by an in-licensed EP4 antagonist that Ikena is testing combined with Keytruda in phase 1b/2 colorectal and non-small cell lung cancer clinical trials. Eli Lilly backed Terns Pharmaceuticals now has two NASH candidates in clinical trials. IND-enabling studies are underway.

RNA 52

RNA Clinical Trials Clinical Trials Bioavailability 52

The Pharma Data

NOVEMBER 22, 2020

EZEPROGIND, which is kicking off phase 2a trials, is a bioavailable neurotrophic inducer. Unlike most products developed by the competition, EZEPROGIND targets all causes of neurodegeneration and is not only aiming at markers such as Abeta protein or Tau protein. View source version on businesswire.com: [link].

Drugs 40

Drugs Protein Bioavailability Development 40

The Pharma Data

AUGUST 16, 2021

Primary and all key secondary endpoints including itch, interference of itch on sleep and quality of life were met at Week 16 in two pivotal Phase 3 trials in lebrikizumab clinical trial program – Safety profile consistent with prior lebrikizumab studies in atopic dermatitis. 1-4 The U.S.

Dermatology 40

Dermatology Trials Bioavailability Medicine 40

Roots Analysis

JANUARY 28, 2024

Pharmaceutical Research: Big data analytics can be applied in various areas of pharmaceutical research, including drug discovery and development, precision medicine , clinical trial optimization, pharmacovigilance and drug safety, supply chain optimization, and real-time monitoring and surveillance.

Big Data 40

Big Data Medicine Marketing Clinical Trials 40

Drug Discovery World

APRIL 17, 2023

New bispecific antibody study results for multiple myeloma According to results of a phase I/II clinical trial presented today, patients with relapsed or refractory multiple myeloma who were treated with the two highest doses of REGN5459, a bispecific antibody targeting BCMA and CD3, experienced a 90.5% Read more here.

Research 52

Research Antibody Bioavailability Genetics 52

Delveinsight

JULY 30, 2020

Adrenoleukodystrophy (ALD/ X-ALD) is a rare, X-linked disorder secondary to a mutation in the ABCD1 gene, which encodes for a peroxisomal membrane protein, resulting in an excessive accumulation of very-long-chain fatty acids (VLCFAs) in the brain and adrenal glands. A novel, brain penetrant, orally bioavailable and selective PPAR?

Hormones 52

Hormones Marketing Gene Trials 52

The Pharma Data

NOVEMBER 19, 2020

Program focused on inhibitors of SARS-CoV-2 main protease, a highly conserved protein essential for viral replication. These compounds have demonstrated high potency in inhibiting the activity of the M pro protease as well as promising oral bioavailability and blood plasma levels in animal studies.

Development 40

Development Bioavailability Production Drugs 40

XTalks

AUGUST 30, 2022

The webinar also featured Kelsey Carter, MS, Clinical Trial Manager at Medpace who discussed the site, operational and regulatory challenges for neuroscience trials with direct CNS administration along with the strategies to mitigate these challenges. What About Small Proteins and Antibodies Reaching Extracellular CNS Targets?

Trials 83

Trials Drug Delivery Drugs Gene 83

Delveinsight

SEPTEMBER 8, 2021

There are several SLE therapies in the pipeline that are under investigation in different phases of clinical trials for the treatment of Systemic Lupus Erythematosus. Baricitinib, also known as LY3009104 or INCB028050 , is a novel orally bioavailable inhibitor of the tyrosine-protein kinase JAK1 or JAK2.

Marketing 52

Marketing Sales FDA Approval Antibody 52